National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 60248-60249 [2020-21117]
Download as PDF
<![CDATA[
60248
Federal Register / Vol. 85, No. 186 / Thursday, September 24, 2020 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Musculoskeletal, Oral
and Skin Sciences Integrated Review Group
Musculoskeletal Rehabilitation Sciences
Study Section.
Date: October 19–20, 2020.
Time: 10:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Maria Nurminskaya, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, Bethesda, MD 20892, (301) 435–1222,
nurminskayam@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel
Musculoskeletal Tissue Engineering.
Date: October 21, 2020.
Time: 10:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Katherine M Malinda,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4140,
MSC 7814, Bethesda, MD 20892, 301–435–
0912, Katherine_Malinda@csr.nih.gov.
Name of Committee: Endocrinology,
Metabolism, Nutrition and Reproductive
Sciences Integrated Review Group Cellular
Aspects of Diabetes and Obesity Study
Section.
Date: October 22–23, 2020.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Elaine Sierra-Rivera, MS,
BS, Ph.D., IRG Chief, EMNR IRG, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6182
VerDate Sep<11>2014
17:00 Sep 23, 2020
Jkt 250001
MSC 7892, Bethesda, MD 20892, 301 435–
2514, riverase@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Fellowships:
Genes, Genomes and Genetics.
Date: October 22–23, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lystranne Alysia Maynard
Smith, Ph.D., Scientific Review Officer,
Center for Scientific Review, National
Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, 301–402–4809,
lystranne.maynard-smith@nih.gov.
Name of Committee: Bioengineering
Sciences & Technologies Integrated Review
Group Biodata Management and Analysis
Study Section.
Date: October 22–23, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Wenchi Liang, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3150,
MSC 7770, Bethesda, MD 20892, 301–435–
0681, liangw3@csr.nih.gov.
Name of Committee: Integrative,
Functional and Cognitive Neuroscience
Integrated Review Group Neurotoxicology
and Alcohol Study Section.
Date: October 22–23, 2020.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Sepandarmaz Aschrafi,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040D,
Bethesda, MD 20892, (301) 451.4251,
Armaz.aschrafi@nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group Macromolecular Structure and
Function D Study Section.
Date: October 23, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ian Frederick Thorpe,
Ph.D., Scientific Review Officer, Center for
Scientific Review, 6701 Rockledge Drive,
Bethesda, MD 20892, (301) 480–8662,
ian.thorpe@nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel Fellowships
in Genes, Genomics and Genetics.
Date: October 23, 2020.
Time: 9:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00124
Fmt 4703
Sfmt 4703
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raj K Krishnaraju, Ph.D.,
MS, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
MSC 7804, Bethesda, MD 20892, (301) 435–
1047, kkrishna@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel PAR Panel:
Global Infectious Disease Training Grants.
Date: October 23, 2020.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Tamara Lyn McNealy,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3188,
Bethesda, MD 20892, 301–827–2372,
tamara.mcnealy@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: September 21, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21125 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Microbiology,
Infectious Diseases and AIDS Initial Review
Group Microbiology and Infectious Diseases
Research Committee.
Date: October 14–15, 2020.
Time: 9:00 a.m. to 5:30 p.m.
E:\FR\FM\24SEN1.SGM
24SEN1
Federal Register / Vol. 85, No. 186 / Thursday, September 24, 2020 / Notices
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Amir E. Zeituni, Ph.D.,
Scientific Review Program, Division of
Extramural Activities, Room 3G51, National
Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers
Lane, Room 3G51, Rockville, MD 20852–
9823, 301–496–2550, amir.zeituni@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: September 21, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–21117 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent Commercialization License:
Method of Treating Periodontal
Disease via ENPP1 Inhibition
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Institute of
Arthritis and Musculoskeletal and Skin
Diseases, of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an exclusive patent
commercialization license to Petragen,
Inc., a start-up company incorporated in
the state of Delaware, to practice the
inventions covered by the patent estate
listed in the Supplementary Information
section of this notice. This notice is
intended to apprise the public of the
aforementioned license and provide a
fifteen (15) day notice period for the
objection.
DATES: Only written comments and/or
applications for a license which are
received by the National Heart, Lung,
and Blood Institute Office of
Technology Transfer and Development
on or before October 9, 2020 will be
considered.
ADDRESSES: Requests for copies of
patent applications (electronic only),
inquiries, and comments relating to the
contemplated an exclusive patent
license should be emailed to: Benfeard
Williams, II, Ph.D., Technology Transfer
Manager, 31 Center Drive, Room 4A29,
SUMMARY:
VerDate Sep<11>2014
17:00 Sep 23, 2020
Jkt 250001
MSC 2479, Bethesda, MD 20892–2479,
phone number 301–435–4507, or
benfeard.williams@nih.gov.
SUPPLEMENTARY INFORMATION:
Intellectual Property (Patent Estate)
HHS Ref. No. E–024–2018–0, U.S.
Provisional Patent Application 62/
590,824 filed November 27, 2017,
International Patent Application PCT/
US2018/062593 filed November 27,
2018, Chinese Patent Application
201880076753.7 filed November 27,
2018, European Patent Application
18816451.1 filed November 27, 2018,
Israeli Patent Application 274529 filed
November 27, 2018 and U.S. Patent
Application 16/765,420 filed May 19,
2020, and any and all continuation or
divisional applications claiming priority
to any of the above.
The patent rights in these inventions
have been assigned or exclusively
licensed to the Government of the
United States of America.
The aforementioned patent estate
covers methods of treating or preventing
periodontal disease in a subject by
administering an inhibitor of ENPP1. In
addition, the claims cover
pharmaceutical compositions for use in
the treatment or prevention of
periodontal disease, or for increasing
cementum formation. In particular, the
dependent claims cover ENPP1
inhibitors comprising analogues of ATP
derivatives, wherein the ENPP1
inhibitor is bound to nanoparticles,
nanofibers, suture materials,
microspheres, polymers, fibers,
matrices, gels, or a combination thereof.
The treatment methods also include
dependent claims wherein treating or
preventing periodontal disease
comprises increasing cementum
formation and wherein the composition
is formulated for injection in gum
tissue, local delivery at a surgical flap,
buccal delivery, delivery by a resorbable
suture, delivery by a wound healing
dressing, or a combination of the
foregoing.
Inhibition of the glycoprotein ENPP1
promotes cementum formation in
mammals. Cementum, an avascular
mineralized tooth root structure,
attaches the tooth to the periodontal
ligament and supporting bone.
Cementum has limited turnover and
subjects with periodontal disease
experience localized loss of cementum
resulting in the detachment of the
periodontal ligament from the tooth
root. Increasing cementum formation
can be used to treat periodontal disease.
The prospective exclusive license
territory may be worldwide and in a
field of use that may be limited to
Therapeutics for periodontitis or
PO 00000
Frm 00125
Fmt 4703
Sfmt 4703
60249
gingivitis, and where the ‘‘Licensed
Products’’ are expected to be inhibitors
of ecto-nucleotide pyrophosphate/
phosphodiesterase-I (ENPP1) within the
scope of the Licensed Patent Rights.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent
commercialization license will be
royalty bearing. The prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Heart, Lung, and Blood Institute Office
of Technology Transfer and
Development receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this notice will be presumed
to contain business confidential
information and any release of
information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: September 17, 2020.
Bruce D. Goldstein,
Director, Office of Technology Transfer and
Development, National Heart, Lung, and
Blood Institute.
[FR Doc. 2020–21060 Filed 9–23–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOUSING AND
URBAN DEVELOPMENT
[Docket No. FR–7024–N–40]
30-Day Notice of Proposed Information
Collection: Project Based Vouchers
(PBV) Data Collection; OMB Control
No.: 2577–NEW Collection
Office of the Chief Information
Officer, Housing and Urban
Development (HUD).
ACTION: Notice.
AGENCY:
HUD has submitted the
proposed information collection
requirement described below to the
Office of Management and Budget
(OMB) for review, in accordance with
the Paperwork Reduction Act. The
purpose of this notice is to allow for an
additional 30 days of public comment.
SUMMARY:
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 85, Number 186 (Thursday, September 24, 2020)]
[Notices]
[Pages 60248-60249]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-21117]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases; Notice of
Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Microbiology, Infectious Diseases and AIDS
Initial Review Group Microbiology and Infectious Diseases Research
Committee.
Date: October 14-15, 2020.
Time: 9:00 a.m. to 5:30 p.m.
[[Page 60249]]
Agenda: To review and evaluate grant applications.
Place: National Institute of Allergy and Infectious Diseases,
National Institutes of Health, 5601 Fishers Lane, Room 3G51,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Amir E. Zeituni, Ph.D., Scientific Review
Program, Division of Extramural Activities, Room 3G51, National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G51, Rockville, MD 20852-9823, 301-
496-2550, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.855,
Allergy, Immunology, and Transplantation Research; 93.856,
Microbiology and Infectious Diseases Research, National Institutes
of Health, HHS)
Dated: September 21, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-21117 Filed 9-23-20; 8:45 am]
BILLING CODE 4140-01-P
